Skip to main content
Clinical Trials/NCT07263165
NCT07263165
Not yet recruiting
Not Applicable

Effect of Adding Dexmedetomidine as Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery. A Prospective Randomized Clinical Trial

Assiut University0 sites54 target enrollmentStarted: December 15, 2025Last updated:
InterventionsDexmedetomidine

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
54
Primary Endpoint
Total Postoperative Opioid Consumption (mg of morphine equivalents)

Overview

Brief Summary

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery.

Detailed Description

Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery. A prospectiverandomized clinical trial

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients aged 18-70 years scheduled for elective upper abdominal cancer surgery (e.g., gastrectomy, hepatectomy, pancreatectomy).
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Body mass index (BMI) between 18-35 kg/m².

Exclusion Criteria

  • Patient refusal.
  • Allergy to local anesthetics or dexmedetomidine.
  • Coagulopathy (INR \>1.5, platelet count \<100,000/mm³).
  • Infection at the injection site.
  • Severe cardiopulmonary, renal, or hepatic dysfunction.
  • Chronic opioid use (\>30 mg morphine equivalents daily for \>3 months).
  • Pregnancy or lactation.

Arms & Interventions

Dexmedetomidine + Bupivacaine

Experimental

Participants will receive an ultrasound-guided external oblique intercostal plane block using 20 mL of 0.25% bupivacaine combined with dexmedetomidine (0.5 µg/kg) administered as a single-shot injection.

Intervention: Dexmedetomidine (Drug)

Bupivicaine

Active Comparator

Participants will receive an ultrasound-guided external oblique intercostal plane block using 20 mL of 0.25% bupivacaine administered as a single-shot injection without any adjuvant.

Intervention: Dexmedetomidine (Drug)

Outcomes

Primary Outcomes

Total Postoperative Opioid Consumption (mg of morphine equivalents)

Time Frame: 24 hours postoperative.

To evaluate the effect of adding dexmedetomidine to bupivacaine on total opioid consumption within the first 24 hours after upper abdominal cancer surgery.

Secondary Outcomes

  • Postoperative Pain Intensity Using the Visual Analog Scale (VAS 0-10)(2, 4, 6, 12, 18, and 24 hours postoperative.)
  • Time to First Request for Rescue Analgesia.(24 hour postoperative)
  • Number of Participants with Adverse Effects(first 2 hours postoperative.)
  • patient satisfaction score(1 hour postoperative)
  • Block-related complications.(intraoperative and 24 postoperative)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mohamed Ibrahem Shaker

Anesthesia Resident

Assiut University

Similar Trials